Evidence map›Paper›PMID 28097802›Full record

ArticlePigment cell & melanoma research2017

Genomic analysis and clinical management of adolescent cutaneous melanoma.

Roy Rabbie, Mamunur Rashid, Ana M Arance, Marcelo Sánchez, Gemma Tell-Marti, Miriam Potrony, Carles Conill, Remco van Doorn, Stefan Dentro, Nelleke A Gruis and 6 more

Open access · hybridAbstract readCase Reports
In one paragraph

Article in Pigment cell & melanoma research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. TNF-alpha and metalloproteases as key players in melanoma cells aggressiveness.Journal of experimental & clinical cancer research : CR · 2018
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 4 countries.

Roy RabbieExperimental Cancer Genetics, The Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, UK.ORCID 0000-0002-9195-5659
Mamunur RashidExperimental Cancer Genetics, The Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, UK.
Ana M AranceDepartment of Medical Oncology and Targeted Therapeutics in Solid Tumors Group (IDIBAPS), Hospital Clınic de Barcelona, Barcelona, Spain.
Marcelo SánchezMelanoma Unit, Radiology Service, Hospital Clınic, IDIBAPS, University of Barcelona, Barcelona, Spain.
Gemma Tell-MartiMelanoma Unit, Department of Dermatology, Hospital Clınic de Barcelona, Barcelona, Spain.
Miriam PotronyMelanoma Unit, Department of Dermatology, Hospital Clınic de Barcelona, IDIBAPS, Barcelona University, Barcelona, Spain.
Carles ConillMelanoma Unit, Radiotherapy Oncology, Hospital Clınic, IDIBAPS, Barcelona University, Barcelona, Spain.
Remco van DoornLeiden University Medical Centre, Leiden, The Netherlands.
Stefan DentroExperimental Cancer Genetics, The Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, UK.
Nelleke A GruisLeiden University Medical Centre, Leiden, The Netherlands.
Pippa CorrieDepartment of Oncology, Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, UK.
Vivek IyerExperimental Cancer Genetics, The Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, UK.
Carla Daniela Robles-EspinozaExperimental Cancer Genetics, The Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, UK.ORCID 0000-0003-3277-7466
Joan A Puig-ButilleCentre of Biomedical Research on Rare Diseases (CIBERER), ISCIII, Barcelona, Spain.
Susana PuigMelanoma Unit, Department of Dermatology, Hospital Clınic de Barcelona, Barcelona, Spain.
David J AdamsExperimental Cancer Genetics, The Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, UK.ORCID 0000-0001-9490-0306
Hospital Clínic de Barcelona · ESWellcome Sanger Institute · GBInstituto de Salud Carlos III · ESLeiden University Medical Center · NLNational Health Service · GBAutonomous University of Queretaro · MX

Funding

Cancer Research UK 13031Wellcome Trust
6 · The paper itself

Abstract

Melanoma in young children is rare; however, its incidence in adolescents and young adults is rising. We describe the clinical course of a 15-year-old female diagnosed with AJCC stage IB non-ulcerated primary melanoma, who died from metastatic disease 4 years after diagnosis despite three lines of modern systemic therapy. We also present the complete genomic profile of her tumour and compare this to a further series of 13 adolescent melanomas and 275 adult cutaneous melanomas. A somatic BRAF

Indexed as

GenomicsAdolescentCutaneous Malignant MelanomaFemaleGerm CellsHumansMaleMelanomaPedigreePositron Emission Tomography Computed TomographySkin Neoplasmsadolescent melanomaBRAF mutationgermline mutationimmunotherapyultraviolet radiation

Identifiers

PMID28097802
PMCPMC5435926
OpenAlexW2579541716

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.